Feasibility and safety of a novel indwelling catheter system via the femoral artery for intermittent transarterial therapy for treating malignant liver tumors.
Hepatic arterial infusion chemotherapy
Hepatocellular carcinoma
Interventional radiology
Solid tumors
Transcatheter arterial chemoembolization
Journal
Japanese journal of radiology
ISSN: 1867-108X
Titre abrégé: Jpn J Radiol
Pays: Japan
ID NLM: 101490689
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
07
04
2021
accepted:
21
09
2021
pubmed:
27
10
2021
medline:
5
3
2022
entrez:
26
10
2021
Statut:
ppublish
Résumé
An indwelling arterial access system via the brachial artery, System-i, has been previously reported. We have modified the technique for the femoral artery approach. This study aimed to evaluate the feasibility and safety of the modified System-i for patients with malignant liver tumors. The modified System-i is an indwelling catheter that provides vascular access for inserting a microcatheter without repeated punctures to the femoral artery. Between 2018 and 2020, the system was implanted for 50 patients with malignant liver tumors. We used the system for patients with difficulty in inserting the conventional indwelling catheter system. To place the system, a side-holed catheter was implanted in the femoral artery, and the tip of the catheter was placed in the superficial femoral artery through the contralateral iliac artery. Using this system, transcatheter arterial chemoembolization or hepatic arterial infusion chemotherapy was performed. A shaped high-flow microcatheter and a non-tapered microcatheter were used with the system. The technical aspects and outcomes of the system were also assessed. Implantation of the system was successful in all patients. The median implantation time was 40 min. The main reason for implantation was obstruction or stenosis of the hepatic artery. Among the 50 patients, 11 (22%) showed complications, of which four had major complications/class C based on the SIR criteria. The modified System-i is a safe system that can be a feasible repeated interventional radiological treatment via the femoral approach. We need to evaluate the efficacy of this system in the treatment of advanced cancers in the future. The modified System-i is a novel indwelling catheter system that allows vascular access to perform intermittent transarterial therapy, such as transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy via the femoral approach. In this study, we report the technical details and safety of the system.
Identifiants
pubmed: 34699022
doi: 10.1007/s11604-021-01202-9
pii: 10.1007/s11604-021-01202-9
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
326-333Informations de copyright
© 2021. Japan Radiological Society.
Références
Torimura T, Iwamoto H. Optimizing the management of intermediate-stage HCC: current trends and prospects. Clin Mol Hepatol. 2020;27(2):236–45 (Epub 2020/12/03).
doi: 10.3350/cmh.2020.0204
Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, et al. Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? Jpn J Radiol. 2012;30(7):560–6.
doi: 10.1007/s11604-012-0088-1
Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, et al. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: a prospective cohort study. Mol Clin Oncol. 2017;7(6):1013–20 (Epub 2017/10/04).
pubmed: 29285366
pmcid: 5740831
Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020;35(8):1277–87 (Epub 2020/02/13).
doi: 10.1111/jgh.15010
Hu J, Bao Q, Cao G, Zhu X, Yang R, Ji X, et al. Hepatic arterial infusion chemotherapy using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis. Cardiovasc Intervent Radiol. 2020;43(7):996–1005 (Epub 2020/01/23).
doi: 10.1007/s00270-019-02406-3
He M, Li Q, Zou R, Shen J, Fang W, Tan G, et al. Sorafenib Plus Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–60.
doi: 10.1001/jamaoncol.2019.0250
Ikeda M, Okusaka T, Furuse J, Mitsunaga S, Ueno H, Yamaura H, et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2013;72(2):463–70 (Epub 2013/06/29).
doi: 10.1007/s00280-013-2222-x
Heger N, Bayindir S, Steckenmesser R, Schirmer H. Percutaneous catheter-arteriographies: Seldinger technique. Minn Med. 1970;53(10):1093–7.
pubmed: 5469853
Oberfield RA, McCaffrey JA, Polio J, Clouse ME, Hamilton T. Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary. Cancer. 1979;44(2):414–23.
doi: 10.1002/1097-0142(197908)44:2<414::AID-CNCR2820440207>3.0.CO;2-3
Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy. Liver Cancer. 2015;4(3):188–99 (Epub 2015/08/12).
doi: 10.1159/000367746
Itano O, Itano S, Nagamatsu H, Tsutsui R, Deguchi A, Inoue M, et al. Intermittent transcatheter therapy through a new indwelling catheter system for patients with hepatocellular carcinoma. Jpn J Radiol. 2014;32(11):670–5 (Epub 2014/09/27).
doi: 10.1007/s11604-014-0361-6
Shimohira M, Ogino H, Kawai T, Kushita A, Watanabe M, Kawaguchi T, et al. Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma. Br J Radiol. 2011;84(998):184–7.
doi: 10.1259/bjr/26974088
Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, et al. Survival benefit of hepatic arterial infusion chemotherapy over sorafenib in the treatment of locally progressed hepatocellular carcinoma. Cancers. 2021;13(4) (Epub 20210205).
doi: 10.3390/cancers13040646
Khalilzadeh O, Baerlocher MO, Shyn PB, Connolly BL, Devane AM, Morris CS, et al. Proposal of a new adverse event classification by the society of interventional radiology standards of practice committee. J Vasc Interv Radiol. 2017;28(10):1432-7.e3 (Epub 2017/07/27).
doi: 10.1016/j.jvir.2017.06.019
Murata S, Tajima H, Abe Y, Komada Y, Fukunaga T, Nakazawa K, et al. Transcatheter management for multiple liver tumors after hepatic artery obstruction following reservoir placement. Hepatogastroenterology. 2005;52(63):852–6.
pubmed: 15966219
Miyayama S, Matsui O, Taki K, Minami T, Ryu Y, Ito C, et al. Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization. Cardiovasc Intervent Radiol. 2006;29(1):39–48.
doi: 10.1007/s00270-004-0287-y
Miyayama S, Matsui O, Taki K, Minami T, Ito C, Shinmura R, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma fed by the reconstructed inferior phrenic artery: anatomical and technical analysis. J Vasc Interv Radiol. 2004;15(8):815–23.
doi: 10.1097/01.RVI.0000136986.34890.D7
Miyayama S, Matsui O, Nishida H, Yamamori S, Minami T, Shinmura R, et al. Transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma fed by the cystic artery. J Vasc Interv Radiol. 2003;14(9 Pt 1):1155–61.
doi: 10.1097/01.RVI.0000086534.86489.10
Miyayama S, Yamashiro M, Shibata Y, Hashimoto M, Yoshida M, Tsuji K, et al. Variations in feeding arteries of hepatocellular carcinoma located in the left hepatic lobe. Jpn J Radiol. 2012;30(6):471–9 (Epub 2012/04/03).
doi: 10.1007/s11604-012-0075-6